Pfizer’s Oncology Pipeline and Market Prospects

Pfizer, once a pandemic-era market darling, has seen its shares plummet by 50% since 2022. Investors eyeing a potential rebound should focus on three critical factors, with the company's oncology pipeline taking center stage.

The drugmaker's $43 billion acquisition of Seagen underscores its ambition to dominate the oncology market. Seagen's innovative pipeline, combined with Pfizer's resources, aims to deliver breakthrough cancer treatments. "We're acquiring the goose that lays the golden eggs," Pfizer's CEO remarked, signaling long-term confidence in the strategy.

Beyond acquisitions, Pfizer continues to expand its oncology portfolio, betting heavily on this high-growth sector. The success of these efforts will likely determine whether the stock can reverse its downward trajectory.